Last reviewed · How we verify
NCT05787418
HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2
Phase 3 trial testing HH-120 Nasal Spray in COVID-19 in 1,200 participants. Enrolling by invitation.
31 December 2025
Quick facts
| Lead sponsor | Huahui Health |
|---|---|
| Phase | Phase 3 |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 1,200 |
| Start date | 31 March 2023 |
| Primary completion | 31 December 2025 |
| Estimated completion | 1 April 2026 |
| Sites | 2 locations across China |
Drugs / interventions tested
- HH-120 Nasal Spray — full drug profile →
- Placebo
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Huahui Health — full company profile →
Who can join
Adults 12 to 85, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will assess the efficacy of HH-120 nasal spray in participants for the post-exposure prevention of SARS-CoV-2.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
An IgM-like inhalable ACE2 fusion protein broadly neutralizes SARS-CoV-2 variants.
Liu J, Mao F, Chen J, Lu S, et al · · 2023 · cited 22× · PMID 37626079 · DOI 10.1038/s41467-023-40933-3 -
SARS-CoV-2 Omicron: Viral Evolution, Immune Evasion, and Alternative Durable Therapeutic Strategies.
Guo H, Ha S, Botten JW, Xu K, et al · · 2024 · cited 10× · PMID 38793580 · DOI 10.3390/v16050697
Verify or expand the search:
- PubMed search for NCT05787418
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HH-120 Nasal Spray
Trials testing the same drug.
- NCT05659602 — A Clinical Study to Assess Preliminary Efficacy, Safety and Tolerability of HH-120 Nasal Spray in COVID-19 Patients · NA · completed
- NCT05747677 — A Study of HH-120 Nasal Spray in Close Contacts of Those Diagnosed With COVID-19 · NA · completed
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Huahui Health trials
Trials by the same sponsor.
- NCT07519330 — Clinical Study to Evaluate the Efficacy and Safety of HH-006 in Patients With Chronic Hepatitis B Virus Infection · Phase 2 · not yet recruiting
- NCT07499544 — A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear S · Phase 3 · not yet recruiting
- NCT07515209 — A Clinical Study of HH-006 in Untreated Chronic Hepatitis B Virus Infected Patients · Phase 1 · completed
- NCT05861674 — A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection · Phase 2 · completed
- NCT05713318 — A Study To Assess The Efficacy and Safety of HH-120 Nasal Spray for the Treatment of Mild COVID-19 · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05787418 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Huahui Health
- Last refreshed: 10 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05787418.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing